New developments in osteoporosis

Comprehensive Therapy

Volumn 23, Issue 12, 1997, Pages 798-803

  Mcclung, Michael R ^a,b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; RALOXIFENE; SALCATONIN; VITAMIN D;

ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; DIET SUPPLEMENTATION; DRUG EFFICACY; FRACTURE; HUMAN; INTRANASAL DRUG ADMINISTRATION; OSTEOPOROSIS; RISK FACTOR; RISK MANAGEMENT;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCITONIN; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS;

EID: 0030678551     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Consensus Development Conference: Diagnosis, prophylaxis and treatment osteoporosis. Am J Med. 1993;94:646-650.
2. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites is predictive of hip fractures. Lancet. 1993;341: 72-75.
3. Ross PD, Davis JW, Epstein RS, Wasnich RD. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
4. Miller PD, McClung MR. Prediction of fracture risk I: bone density. Am J Med Sci. 1996;312:257-259.
5. Kanis JA, the WHO Study Group. WHO Study Document: assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int. 1994;4:368-381.
6. Ettinger B, Miller PD, McClung MR. Use of bone density results for deciding about therapy for osteoporosis. Ann Intern Med 1996;125:623. Letter.
7. Eastell R, Riggs BL. Diagnostic evaluation of osteoporosis. Endocrin Clin N Am. 1988;17:547-571.
8. Ross PD. Prediction of fracture risk II: other risk factors. Am J Med Sci. 1996;312:260-269.
9. Kleerekoper M. Biochemical markers of bone remodeling. Am J Med Sci. 1996;312:270-277.
10. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fractures in elderly women: the EPI-DOS prospective study. J Bone Miner Res. 1996;11:531-1538.
11. Chesnut CH III. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapy and predicts response of bone mineral density. Am J Med. 1997;102:29-37.
12. Silverman SL. Calcitonin. Am J Med Sci. 1997;313:17-22.
13. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556-561.
14. Liberman U, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1996; 333:1437-1443.
15. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
16. DeGroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of oral alendronate. N Engl J Med. 1996;335:1016-1021
17. McClung MR, Clemmesen B, Daifotis A, et al. Alendronate in the prevention of postmenopausal bone loss. Ann Intern Med. 1997;In press.
18. Hosking DJ, Chivers C, Christiansen C, et al. Prevention of early postmenopausal bone loss with oral alendronate. N Engl J Med. 1997;In press.
19. Lauritzen JB, Petersen MM, Lund B Effect of external hip protectors on hip fractures. Lancet. 1993;341:11-13.